Multiple Sclerosis Drugs Market to Rise at CAGR of 5.9% during Forecast Period, notes TMR Study

·6 min read
  • The market for multiple sclerosis drugs is anticipated to rise more quickly throughout the projected period due to an increasing number of prospective pipeline drug development programs

  • An increase in multiple sclerosis cases is likely to lead to higher demand in the global multiple sclerosis drugs market

WILMINGTON, Del., Aug. 16, 2022 /PRNewswire/ -- The value of global multiple sclerosis drugs market size was clocked at US$ 20 Bn in 2019. The global market is anticipated to attain valuation of US$ 31.5 Bn by 2027. The global multiple sclerosis drugs market projections predict the market to develop at a CAGR of 5.9% during the forecast period, from 219 to 2027. The huge increase in research initiatives aimed at finding novel multiple sclerosis medications with increased efficacy is principally responsible for the market's expansion. Stakeholders should prioritize getting their recently produced multiple sclerosis medications approved by the FDA while also focusing on mergers and acquisitions to increase their market share. Introduction of new drugs and its subsequent approval from FDA are the emerging trends of the multiple sclerosis drugs market.

TMR
TMR

Governmental and non-governmental organizations in developing and developed countries are speeding up their efforts to raise awareness regarding multiple sclerosis and are spending significant amounts of money for research and the development of novel medications.

The development of the global market for multiple sclerosis drugs is anticipated to be significantly influenced by advancements made in the life sciences and healthcare over the last decade. Additionally, growing prevalence of multiple sclerosis, increasing number of promising pipeline drug development programs, and unaddressed requirements in the realm of multiple sclerosis are anticipated to present growth prospects for the companies in the multiple sclerosis drugs market.

Get Exclusive PDF Sample Copy of Multiple Sclerosis Drugs Market Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1130

Key Findings of Market Report

  • Improved outcomes are promised by a new multiple sclerosis drug under development. While there is no proven cure for multiple sclerosis, novel drugs are increasingly being used to control symptoms and slow down the disease's development. Several other multiple sclerosis therapies are in the research pipeline and are anticipated to join the global market, despite the FDA's clearance for novel drugs and treatments.

  • Global multiple sclerosis prevalence and occurrences are expected to rise, along with public awareness about the disease, which is expected to propel the market during the forecast period.

  • Based on drug class, the interferon beta category accounted for a sizable portion of the market for drugs for multiple sclerosis in 2018. The market for is expected to be dominated by monoclonal antibodies throughout the projected period.

Ask for References – https://www.transparencymarketresearch.com/sample/sample.php?flag=ARF&rep_id=1130

Global Multiple Sclerosis Drugs Market: Growth Drivers

  • Regarding distribution channels, the retail pharmacies & drug stores category is anticipated to account for a substantial multiple sclerosis drugs market share and lead the market in the near future.

  • Due to the huge patient population with RRMS, the parenteral mode of administration category is anticipated to grow at a faster CAGR throughout the forecast period. Approximately 75% to 85% of people with MS also suffer RRMS.

Global Multiple Sclerosis Drugs Market: Key Players

Some of the key market players are

  • Acorda Therapeutics, Inc.

  • Teva Pharmaceutical Industries Ltd

  • F. Hoffmann-La Roche Ltd

  • EMD Serono (Merck KGaA)

  • Novartis AG

  • AbbVie, Inc.

Make an Enquiry Before Buying – https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=1130

Global Multiple Sclerosis Drugs Market: Segmentation

Drug Class

  • Interferon Beta

  • Sphingosine 1 Phosphate Receptor Modulators

  • Mixed Polymers

  • NF-KB Inhibitor

  • Pyrimidine Synthesis Inhibitor

  • Monoclonal Antibodies

  • Corticosteroids

  • Adrenocorticotropic Hormone

  • Others

Disease Type

  • Relapsing-remitting MS (RRMS)

  • Primary-progressive MS (PPMS)

  • Secondary-progressive MS (SPMS)

  • Progressive-relapsing MS (PRMS)

Route of Administration

  • Parenteral

  • Oral

Distribution Channel

  • Hospital Pharmacies

  • Retail Pharmacies & Drug Stores

  • Online Pharmacies

Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Latest Healthcare Research Reports by Transparency Market Research:

Wearable Bioelectronic Skin Patches Market: The global wearable bioelectronic skin patches market is expected to reach value of US$ 14.8 Bn by the end of 2031.

Skin Care Devices Market: The global skincare devices market is expected to reach the value of US$ 23.9 Bn by the end of 2028. It is estimated to expand at a CAGR of 9.9% from 2021 to 2028.

Personal-use Facial and Skin Therapy Devices Market: The U.S. personal-use facial and skin therapy devices market is expected to reach the value of US$ 7.5 Bn by the end of 2031.

Meningococcal Vaccines Market: The meningococcal vaccines market is expected to reach a value of US$ 9.2 Bn by the end of 2031. It is estimated to expand at a CAGR of 9.4% from 2022 to 2031.

Geriatric Care Services Market: The global geriatric care services market is expected to reach the value of US$ 0.7 Bn by the end of 2028. It is estimated to expand at a CAGR of 5.3% from 2021 to 2028.

Diagnostic Reagents Market: The global diagnostic reagents market is anticipated to reach more than US$ 85.8 Bn by the end of 2031. The global market is projected to grow at a CAGR of 6.5% from 2022 to 2031.

Microbiology Culture Market: The U.S. microbiology culture market is expected to reach the value of US$ 5.4 Bn by the end of 2031. It is estimated to expand at a CAGR of 7.8% from 2021 to 2031.

Bioinformatics Market: The global bioinformatics market is expected to reach the value of US$ 44.9 Bn by the end of 2028. It is estimated to expand at a CAGR of 5.9% from 2021 to 2028.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact:
Rohit Bhisey
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Websitehttps://www.transparencymarketresearch.com
Bloghttps://tmrblog.com
Email: sales@transparencymarketresearch.com

Logo: https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/multiple-sclerosis-drugs-market-to-rise-at-cagr-of-5-9-during-forecast-period-notes-tmr-study-301605521.html

SOURCE Transparency Market Research